The company on Wednesday forecast revenue from its COVID-19 vaccine and treatment to be $8 billion in 2024, a far cry from the $57 billion in 2022. In March, Pfizer announced a $43 billion acquisition of drugmaker Seagen to bring into its fold four approved cancer therapies. Last year, the company struck an $11.6 billion deal for migraine drug maker Biohaven Pharmaceutical Holding and bought Global Blood Therapeutics for $5.4 billion, adding sickle cell disease treatment Oxbryta to its pipeline.